Days Of Hyperbaric Oxygen Therapy Research Articles

The role, safety, and efficacy of hyperbaric oxygen therapy in aesthetic practice-An evidence-based review.

Hyperbaric oxygen therapy (HBOT) involves patients breathing 100% oxygen in a pressurized chamber, above 1 atmosphere. Many centers are now promoting the use of HBOT for skin rejuvenation. However, the current indications for HBOT do not encompass aesthetic applications. The aim of this evidence-based review was to assess the existing literature regarding the utilization of HBOT in medical aesthetics and rejuvenation, evaluate its effectiveness and safety, and conduct a cost analysis. PubMed Interface, Cochrane Library, Google Scholar, and Embase searches were carried out. The Best Bets methodology was used, and the risk of bias was appraised using the Quality Assessment Tool for Quantitative Studies. This review included a total of 17 human studies with a total of 766 participants. Three studies were classified as level II evidence, three studies were of level III evidence, and 11 were of level IV evidence. All the included studies were judged at high risk of bias. The most relevant findings supported by level II evidence were that HBOT decreased the shedding rate post-FUE hair transplant (27.6 ± 2.6% vs. 69.1 ± 2.4%) but this did not affect the final outcome between HBOT (96.9 ± 0.5%) and the control (93.8 ± 0.6%). Moreover, level III evidence demonstrated that following HBOT, there was a significant increase in elastic fiber length (p ≤ 0.0001, effect size = 2.71) and a significant decrease in fiber fragmentation (p = 0.012). There was also a significant increase in collagen fiber density following HBOT (p = 0.0001, effect size = 1.10). However, there was no significant effect of antioxidant vitamins A, C, and E with HBOT. The inflammatory response significantly decreased after 7 days of HBOT with a decreased expression of IL-12p40, MIP-1β, and PDGF-BB and a higher expression of IL-1Ra. Moreover, HBOT was used prophylactically prior to abdominoplasty to decrease the risk of complications. In this study, complications were decreased from 32.6% (89 patients) to 8.4% (7 patients) with a p < 0.001, and in a multivariate analysis, preoperative HBOT was an independent protective factor against postoperative complications (p < 0.001). There is conflicting evidence on how the method of action of HBOT can have a beneficiary effect in aesthetic and whether the treatment is justifiable. To our knowledge, this is the first comprehensive review discussing the available evidence regarding the use of HBOT in many aesthetic clinical scenarios, including preventive, medical, and surgical settings. However, randomized clinical trials with longer follow-up and better patient selection are needed to be able to generate a reliable conclusion.

PD19-12 PATIENT REPORTED OUTCOME MEASURES FOLLOWING HYPERBARIC OXYGEN THERAPY FOR RADIATION CYSTITIS

You have accessJournal of UrologyCME1 Apr 2023PD19-12 PATIENT REPORTED OUTCOME MEASURES FOLLOWING HYPERBARIC OXYGEN THERAPY FOR RADIATION CYSTITIS Rachel A. Moses, Alexandra Hunter, Eileen R. Brandes, Devin R. Cowan, Nicole P. Harlan, Judy R. Rees, Kevin R. Krughoff, William Bihrle, and Jay C. Buckey Rachel A. MosesRachel A. Moses More articles by this author , Alexandra HunterAlexandra Hunter More articles by this author , Eileen R. BrandesEileen R. Brandes More articles by this author , Devin R. CowanDevin R. Cowan More articles by this author , Nicole P. HarlanNicole P. Harlan More articles by this author , Judy R. ReesJudy R. Rees More articles by this author , Kevin R. KrughoffKevin R. Krughoff More articles by this author , William BihrleWilliam Bihrle More articles by this author , and Jay C. BuckeyJay C. Buckey More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003285.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prior studies demonstrate reduced bladder bleeding interventions after hyperbaric oxygen therapy (HBOT) for hemorrhagic radiation cystitis. Previously, we demonstrated feasibility of collecting urine-related patient reported outcome measures (PROMs) via the Multicenter Registry for HBOT. The purpose of this study is to evaluate change in urine related PROMs before and after HBOT in a larger, updated cohort. METHODS: Prospectively collected data from 19 sites in the Multicenter Registry for Hyperbaric Oxygen Therapy Consortium were analyzed. Measures included a hematuria scale adapted from the Radiation Therapy Oncology Group (RTOG) radiation cystitis scale and the Urinary Distress Inventory (UDI). Data obtained on the first and last days of HBOT were compared using the Wilcoxon rank sum test. RESULTS: 216 patients were included, 197 had complete RTOG/EROTC hematuria data, 146 had UDI data and 133 had both. Patients were on average 72 (+/-10.3) years old, 58/216 were diabetic, 81/216 were current or former smokers, and 187/216 developed radiation cystitis due to prostate cancer related radiation treatment. Referral for HBOT occurred approximately 7.0+/-5.8yrs following radiation. The average number of treatments was 36+/-11. RTOG/EROTC hematuria scores were significantly improved post HBOT (2.2 pre vs 0.9 post, p=0.001) (Figure 1A). UDI scores were significantly improved, post HBOT (61.5+/-31.5 pre vs 49.1+/-30.9, p<0.01) (Figure 1B). CONCLUSIONS: In a novel, multi-institutional prospective data set, we demonstrate HBOT is associated with improved urine related PROMs for individuals undergoing HBOT for radiation cystitis. Continued expansion of the registry may provide more generalizable results and allow for analysis of factors leading to change in UDI and hematuria scores. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e582 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Rachel A. Moses More articles by this author Alexandra Hunter More articles by this author Eileen R. Brandes More articles by this author Devin R. Cowan More articles by this author Nicole P. Harlan More articles by this author Judy R. Rees More articles by this author Kevin R. Krughoff More articles by this author William Bihrle More articles by this author Jay C. Buckey More articles by this author Expand All Advertisement PDF downloadLoading ...

Role of Hyperbaric Oxygen Therapy in Severe Posterior Reversible Encephalopathy Syndrome

ABSTRACT Once considered to be reversible on the elimination of potential triggers, it is now known that severe form of posterior reversible encephalopathy syndrome (PRES) is associated with long-term morbidity and mortality. A 28-year-old female with severe PRES failed to show reversibility of symptoms with conservative management. Along with standard intensive care unit care, she was then given hyperbaric oxygen therapy (HBOT) for 7 days, 2 sessions per day, each session at 2 atm for 90 min. Baseline coma recovery score (CRS) was 0, when the diagnosis of severe PRES was made. At day 7 before start of HBOT, CRS-0 was 4. At the 1st, 5th, and 7th day of HBOT, CRS-1/5/7 was 5/12/19, respectively. She made significant recovery and discharged 18 days from admission. HBOT may reduce morbidity and mortality associated with severe PRES and might prove to be a treatment option allowing faster recovery.

Hyperbaric Oxygen Therapy Following Cervical Spinal Cord Injury Increases BDNF/TrkB Signaling in Diaphragm Muscle

Respiratory insufficiency is the leading cause of morbidity and mortality following cervical spinal cord injury (SCI). Diaphragm atrophy following SCI occurs as a result of damage to respiratory neural circuitry, which leads to impaired muscle contractility. Disruption of redox balance occurs after SCI and increased mitochondrial reactive oxygen species production is an upstream trigger for diaphragm muscle atrophy and weakness. Recently, we demonstrated that increased antioxidant capacity in response to hyperbaric oxygen (HBO) therapy may play a role in preserving mitochondrial redox homeostasis following SCI. However, a precise understanding of the mechanisms by which HBO therapy can prevent diaphragm dysfunction is lacking. In this regard, evidence indicates that the secretion of neurotrophic factors, such as brain derived neurotrophic factor (BDNF), may also contribute to enhanced functional recovery when HBO therapy is initiated acutely following cervical SCI. Through activation of the 5′ adenosine monophosphate‐activated protein kinase (AMPK) and serine‐threonine protein kinase (AKT) signaling via the phosphorylation of its receptor tropomyosin receptor kinase B (TrKb), BDNF expression has been shown to modulate mitochondrial biogenesis and skeletal muscle proteolysis. Therefore, we tested the hypothesis that 10 days of HBO therapy initiated in the acute phase following cervical SCI can increase diaphragm mitochondrial biogenesis and prevent diaphragm proteolytic signaling by activating BDNF/TrkB signaling. To test this, adult male Sprague‐Dawley rats were separated into three groups (n=8/group): (1) non‐injured, room air exposure (CON); (2) lateral‐cervical spinal cord contusion, room air exposure (SCI); and (3) lateral‐cervical spinal cord contusion, HBO therapy (SCI+HBO). Animals in the SCI and SCI+HBO groups were anesthetized, and following laminectomy at the C3–C4 level, a lateral‐cervical spinal contusion was made using a mechanical impactor. HBO therapy consisted of 10 days of exposure starting on the day of SCI, using a 40 L chamber flushed with 100% O2 and pressurized to 3 ATA. Our results indicate that HBO therapy delivered in the acute phase of SCI positively affected BDNF/TrkB signaling. Specifically, diaphragm protein expression of BDNF, p‐AKT/AKT and p‐AMPK/AMPK were increased after 10 days of HBO therapy compared to CON animals (p&lt;0.05). Additionally, HBO therapy prevented the SCI‐induced reduction in diaphragm peroxisome proliferator‐activated receptor‐gamma coactivator (PGC1‐α) protein expression (p&lt;0.05), as well as the caspase‐3‐specific cleavage of α‐II‐spectrin observed in the SCI group (p&lt;0.05). In summary, these findings demonstrate that HBO therapy can induce BDNF signaling and highlight an additional mechanism for the protective effects of HBO therapy to preserve diaphragm muscle function following SCI.

Diaphragm EMG activity during hyperbaric oxygen exposure in spinal injured rats

Cervical spinal cord injury can cause significant respiratory dysfunction and in severe cases necessitates mechanical ventilation. Accumulating evidence indicates that hyperbaric oxygen (HBO) therapy, initiated shortly after spinal cord injury (SCI), can mitigate spinal cord pathology. Further, a recent study from our group demonstrated that HBO therapy can attenuate diaphragm atrophy after SCI. The primary purpose of the present investigation was to evaluate diaphragm electromyogram (EMG) activity during HBO therapy in rats with cervical SCI. HBO therapy has not been widely adopted after SCI, and if HBO is to be translated to human use, we reasoned that it is important to determine how breathing is impacted during HBO exposure. Adult female Sprague‐Dawley rats were implanted with chronic indwelling EMG electrodes in the mid‐costal diaphragm two weeks prior to SCI. Following hemicontusion injury of the C4 spinal cord, one experimental group was treated with HBO (n=3), and another group was left untreated (n=3). The HBO treatment consisted of a one hour exposure to 100% O2 at 3 atmospheres (ATA). In all experiments, diaphragm EMG activity was recorded in freely moving rats, without anesthesia. Recordings were made for 10 minutes prior to treatment, throughout the HBO exposure, and for 10 minutes after. Diaphragm EMG recordings in the normobaric normoxia control group conditions were completed for the same duration of time as the treated group. Daily HBO treatment and EMG recordings were done until 10‐days post‐SCI. Peak diaphragm EMG burst amplitude was quantified before SCI, over the 10 days of treatment, and at 1 and 2 weeks post‐treatment. Prior to SCI, body weight was similar between groups (control: 227±4 g; HBO: 228±3 g). All rats with tolerated HBO treatment with no evidence of adverse events or impact on weight gain over the 10 day period (10 day body weight: control: 198 ± 14 g; HBO: 197 ± 13 g). The acute HBO exposure caused an increase in the area under the curve of the rectified and integrated inspiratory burst amplitude of the diaphragm recording made ipsilateral to the lesion. This increase averaged 126 ± 18% of baseline across the 10 HBO treatments. The ipsilateral EMG burst amplitude also remained elevated at 10 min post‐HBO exposure (115 ± 32%) compared to pre HBO exposure. At the conclusion of the 10 day treatment paradigm, ipsilateral diaphragm EMG output during quiet breathing was elevated in HBO (156 ± 50% of post‐injury baseline) as compared to the control group (111 ± 6% of baseline). However the ipsilateral diaphragm EMG burst amplitude of the two groups were similar when evaluated 2 weeks after the daily HBO sessions concluded. This ongoing study indicates that acute exposure to HBO therapy is associated with an increase in diaphragm EMG activity, and 10 days of HBO therapy accelerates the recovery of diaphragm activation following cervical contusion injury.

The neuroprotective effects of oxygen therapy in Alzheimer’s disease: a narrative review

Alzheimer’s disease (AD) is a degenerative neurological disease that primarily affects the elderly. Drug therapy is the main strategy for AD treatment, but current treatments suffer from poor efficacy and a number of side effects. Non-drug therapy is attracting more attention and may be a better strategy for treatment of AD. Hypoxia is one of the important factors that contribute to the pathogenesis of AD. Multiple cellular processes synergistically promote hypoxia, including aging, hypertension, diabetes, hypoxia/obstructive sleep apnea, obesity, and traumatic brain injury. Increasing evidence has shown that hypoxia may affect multiple pathological aspects of AD, such as amyloid-beta metabolism, tau phosphorylation, autophagy, neuroinflammation, oxidative stress, endoplasmic reticulum stress, and mitochondrial and synaptic dysfunction. Treatments targeting hypoxia may delay or mitigate the progression of AD. Numerous studies have shown that oxygen therapy could improve the risk factors and clinical symptoms of AD. Increasing evidence also suggests that oxygen therapy may improve many pathological aspects of AD including amyloid-beta metabolism, tau phosphorylation, neuroinflammation, neuronal apoptosis, oxidative stress, neurotrophic factors, mitochondrial function, cerebral blood volume, and protein synthesis. In this review, we summarized the effects of oxygen therapy on AD pathogenesis and the mechanisms underlying these alterations. We expect that this review can benefit future clinical applications and therapy strategies on oxygen therapy for AD.

Hyperbaric Oxygen Therapy for Pain, Opioid Withdrawal, and Related Symptoms: A Pilot Randomized Controlled Trial

BackgroundPain, drug cravings, and opioid withdrawal symptoms can interfere with substance use disorder or opioid tapering treatment goals. AimThis pilot study investigated the feasibility of a protocol designed to test opioid withdrawal symptom relief relative to a sham condition after two consecutive days of hyperbaric oxygen therapy (HBOT) for adults prescribed daily methadone for opioid use disorder. MethodUsing a double-blind protocol, eight adults were randomized to receive either a full 90-minute HBOT dose in a pressurized chamber with 100% oxygen at 2.0 atmospheres absolute (ATA) or a sham condition receiving 21% oxygen (equivalent to room air within the chamber) at a minimal pressure of ≤1.3 ATA. Measures included study retention, treatment satisfaction, and pre- and post-intervention effects for opioid withdrawal symptoms, drug cravings, pain intensity and interference, sleep quality, and mood. ResultsStudy retention and treatment satisfaction was high. All measurements improved more, on average, for participants receiving full-dose HBOT treatment than among participants receiving sham treatments except for clinically observed withdrawal symptoms. The largest positive effects were observed in measurements of pain intensity and drug craving. ConclusionsThese pilot results provide evidence to support a fully powered study of HBOT as a potential treatment adjunct for adults receiving methadone for opioid use disorder. Trends towards symptom improvements were detected from pre- to post-HBOT in the full treatment arm versus sham condition. More research into novel non-pharmacologic options to relieve distressing symptoms related to pain and opioid use disorder is essential to improve clinical outcomes.

Hyperbaric oxygen therapy in overweight and obese patients with COVID‑19

Currently, the global healthcare system is facing a crisis caused by coronavirus disease 2019 (COVID‑19), with a significant number of patients requiring supportive care, particularly to fulfill their respiratory requirements. The current oxygen delivery systems may fail to meet the needs of certain patients or are associated with the appearance of sequelae following their use, such as in cases receiving invasive mechanical ventilation. Hyperbaric oxygen therapy (HBOT) poses an attractive alternative to the current oxygen delivery systems available for patients with COVID‑19. HBOT has been previously used in various types of infectious diseases, providing inflammatory relief and facilitating the reversal of hypoxemia, qualities that may also prove beneficial to patients with COVID‑19. At present, a significant proportion of the population worldwide is overweight or obese, and these comorbidities are considered to increase the severity of COVID‑19 symptoms. The present study aimed to investigate whether HBOT may benefit a representative sample of this aforementioned population (n=36 patients). After the first HBOT session, 7 patients were immediately relieved from shortness of breath, while in 22 patients, this symptom was markedly alleviated after 7.57±0.63 days of HBOT. Moreover, the remaining patients (n=7) had a slow breath recovery after performing activity, suggesting that they should continue HBOT. On the whole, the present study demonstrates that daily HBOT for 7.57±0.63 days improved COVID‑19 symptoms in over half of the enrolled patients, indicating that it may be a useful alternative in the treatment of this illness.

Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats

Background/aim Hyperbaric oxygen therapy (HBOT) causes insulin sensitivity, but the reason for this is not known yet. The aim of the present study was to investigate the effect of HBOT on insulin sensitivity via resistin, plasminogen activator inhibitor-I (PAI - I), and adiponectin.Materials and methods The study was designed using HBOT and control groups, with eight rats in each group. After 20 days of HBOT under 2.5 atmospheres for 90 min, the fasting insulin (FI), resistin, PAI-I, homeostatic model assessment of insulin resistance scores (HOMA–IR), quantitative insulin sensitivity check index (QUICKI), fasting plasma glucose (FPG), triglyceride, and high-density lipoprotein cholesterol (HDL-C) in the plasma were measured. The resistin, PAI-I, and adiponectin mRNA expression levels were also measured in the adipose tissue.ResultsCompared to the control group, the FI, FPG, and HOMA-IR scores were significantly lower in the HBOT group, whereas the HDL-C and QUICKI scores were found to be higher. In addition, the resistin, adiponectin, and PAI-I mRNA expression levels were also higher in the HBOT group.ConclusionThe present study demonstrated that the HBOT had regulated the FI, FPG, and HDL-C associated with metabolic syndrome and diabetes mellitus. Moreover, the study showed that HBOT causes insulin sensitivity by raising adiponectin.

Hyperbaric oxygen therapy caused tympanic membrane and ventricular hemorrhage: a case report

A 40-year-old male undergoing rehabilitation with hyperbaric oxygen therapy (HBOT) three months after an acute right frontal lobe cerebral infarction. On the second day of HBOT, he felt a significant blockage and pain in his left ear during and after the treatment. The endoscopic assessment of the ear and nose revealed haemorrhage in the left ear tympanic membrane and hemorrhagic effusion in the tympanic chamber. The nasal septum was found to be left deviated resulting in significant narrowing of the left nasal cavity and significant poor ventilation. Laboratory tests showed normal blood count and normal blood coagulation count. The final diagnosis of haemorrhage and fluid accumulation in the tympanic chamber of the left ear was made. After the treatment of the middle ear ball blowing once a day for 10 days, the pure tone audiometry of the left ear reached the level of the right ear, and the blockage and pain in the left ear disappeared completely. The orthoscopy inspection indicated total absorption of hemorrhagic fluid in the tympanic chamber of the left ear. This is the first report that HBOT caused tympanic membrane haemorrhage and offers new insights into the prevention of comorbidities in HBOT.

Hyperbaric oxygen therapy in the healing process of foot ulcers in diabetic type 2 patients marked by interleukin 6, vascular endothelial growth factor, and PEDIS score: A randomized controlled trial study

IntroductionDiabetic foot ulcers (DFU) is a major social issue in terms of treatment cost. DFU has a high risk of infection with morbidity and an increased risk of lower-extremity amputations. Currently, there are no satisfactory treatments for DFU. This motivates a search for methods that can stimulate the acceleration of wound healing; one of these methods is the use of hyperbaric oxygen therapy (HBOT). This study attempts to prove the ability of HBOT to accelerate the healing process of DFU by increasing levels of both serum Interleukin 6 (IL-6) and Vascular Endothelial Growth Factor (VEFG), assessed by the perfusion, extent, depth, infection and sensation (PEDIS) score. MethodsTwenty DFU patients were divided into two groups. The control group underwent a holistic DFU treatment without HBOT and was tested twice for serum IL-6 and VEGF levels, 1 day apart. The HBOT group underwent a holistic DFU treatment with HBOT and was also tested twice for serum IL-6 and VEGF levels: one day before HBOT and 2 h after the first day of HBOT. ResultsThe changes in serum IL-6 and VEGF levels were greater in patients with HBOT than in control patients (p = 0.025 and p = 0.004). As for PEDIS score assessment, the HBOT group had significantly lower PEDIS scores than the control group (p < 0.001). ConclusionHBOT can help accelerate the wound healing process, which was proven by increased serum IL-6 and VEGF levels and a lower PEDIS score.

Hyperbaric Oxygen for Radiation Necrosis of the Brain.

Hyperbaric oxygen therapy (HBOT) shows promising results in treating radionecrosis (RN) but there is limited evidence for its use in brain RN. The purpose of this study is to report the outcomes of using HBOT for symptomatic brain RN at a single institution. This was a retrospective review of patients with symptomatic brain RN between 2008 and 2018 and was treated with HBOT. Demographic data, steroid use, clinical response, radiologic response and toxicities were collected. The index time for analysis was the first day of HBOT. The primary endpoint was clinical improvement of a presenting symptom, including steroid dose reduction. Thirteen patients who received HBOT for symptomatic RN were included. The median time from last brain radiation therapy to presenting symptoms of brain RN was 6 months. Twelve patients (92%) had clinical improvement with median time to symptom improvement of 33 days (range 1-109 days). One patient had transient improvement after HBOT but had recurrent symptomatic RN at 12 months. Of the eight patients with evaluable follow-up MRI, four patients had radiological improvement while four had stable necrosis appearance. Two patients had subsequent deterioration in MRI appearances, one each in the background of initial radiologic improvement and stability. Median survival was 15 months with median follow-up of 10 months. Seven patients reported side effects attributable to HBOT (54%), four of which were otologic in origin. HBOT is a safe and effective treatment for brain RN. HBOT showed clinical and radiologic improvement or stability in most patients. Prospective studies to further evaluate the effectiveness and side effects of HBOT are needed.

The impact of hyperbaric oxygen therapy on erectile functions and serum testosterone levels in patients with erectile dysfunction

Objective: To evaluate the effects of hyperbaric oxygen therapy (HBOT) on erectile functions and serum testosterone levels in patients with erectile dysfunction (ED).Methods: The patients treated by HBOT for several diseases between July 2017–May 2018 and had erectile dysfunction were included in the study. All patients filled the International Index of Erectile Function (IIEF) questionnaire form; serum total testosterone (TT) and free testosterone (FT) levels were examined before the first day and after the last day of HBOT. The effects of demographic characteristics of patients on erectile functions were evaluated. Patients were categorized according to the risk factors. The IIEF scores, TT and FT levels of patients in first day and after last day of HBOT were compared.Results: Totally 43 patients were included in the study. The mean post-HBOT IIEF-EF score was significantly higher than the mean pre-HBOT IIEF-EF score of patients (25.4 ± 5.3 vs 20.6 ± 5.1; p < .001). There was no statistical difference between the pre-HBOT and post-HBOT serum TT and FT levels of patients (4.0 ± 2.3 ng/ml vs 4.1 ± 2.0 ng/ml, p = .797; 8.6 ± 3.8 pg/ml vs 8.9 ± 3.5 pg/ml, p = .658).Conclusions: HBOT improved the erectile functions in ED patients however we cannot detect any effect on testosterone levels in our study.

The THE DIFFERENCE OF PHYSICAL DIMENSION IN THE QUALITY OF LIVING ON PATIENTS OF DIABETES MELLITUS BETWEEN GIVING HYPERBARIC OXYGEN THERAPY 10 DAYS AND 5 DAYS

ABSTRACT&#x0D; &#x0D; Quality of life is the subjective perception of the individual to the physical, psychological, social, and environmental conditions experienced. The aim of the study was to analyze differences in the physical dimensions of the quality of life of diabetes mellitus patients between providing hyperbaric oxygen therapy 10 days and 5 days.&#x0D; This study used the quasy experiment method with the approach of pre post test with control group design. The population in the study was 882 people with a sample of 14 respondents divided into two groups. 7 respondents in the treatment group and 7 respondents in the control group. Sampling used was consecutive sampling technique. Data were analyzed using Paired t test and Independent t test.&#x0D; The results of the Paired t test statistic in the treatment group had differences in quality of life before and after 10 days of hyperbaric oxygen therapy, while the control group had no difference in quality of life before and after 5 days of hyperbaric oxygen therapy. The independent t test results were different after being given hyperbaric oxygen therapy 10 days and 5 days.&#x0D; It is expected that health workers can be used as a reference source and as a basis for determining nursing intervention in the management of diabetes, especially in the quality of life of diabetic patients.

The THE DIFFERENCE OF PHYSICAL DIMENSION IN THE QUALITY OF LIVING ON PATIENTS OF DIABETES MELLITUS BETWEEN GIVING HYPERBARIC OXYGEN THERAPY 10 DAYS AND 5 DAYS

ABSTRACT&#x0D; &#x0D; Quality of life is the subjective perception of the individual to the physical, psychological, social, and environmental conditions experienced. The aim of the study was to analyze differences in the physical dimensions of the quality of life of diabetes mellitus patients between providing hyperbaric oxygen therapy 10 days and 5 days.&#x0D; This study used the quasy experiment method with the approach of pre post test with control group design. The population in the study was 882 people with a sample of 14 respondents divided into two groups. 7 respondents in the treatment group and 7 respondents in the control group. Sampling used was consecutive sampling technique. Data were analyzed using Paired t test and Independent t test.&#x0D; The results of the Paired t test statistic in the treatment group had differences in quality of life before and after 10 days of hyperbaric oxygen therapy, while the control group had no difference in quality of life before and after 5 days of hyperbaric oxygen therapy. The independent t test results were different after being given hyperbaric oxygen therapy 10 days and 5 days.&#x0D; It is expected that health workers can be used as a reference source and as a basis for determining nursing intervention in the management of diabetes, especially in the quality of life of diabetic patients.

Impact of the hyperbaric oxygen therapy on the redox status in patients with systemic lupus erythematosus

Background/Aim. Hyperbaric oxygen therapy (HBOT) is a method which increases oxygen solubility in plasma up to 20 times. This effect is very important in the treatment of circulatory disorders, which reduces oxygenation and leads to increased production of inflammatory mediators and free oxygen radicals. The aim of this study was to examine the impact of HBOT on the oxidative stress parameters in the patients with systemic lupus erythematosus (SLE). Methods. This prospective study included 18 females with SLE [American College of Rheumatology (ACR) criteria], average age 52.2 ? 8.82 years, treated with HBOT for 60 min/day, with average partial oxygen pressure of 2.2 atmospheres absolute (ATA), during 10 days, in combination with appropriate medication therapy for SLE. The following parameters were determined in the serum: C-reactive protein (CRP), hemoglobin, creatinine, albumin, complement 3 (C3), antinuclear antibodies (ANA), glomerular filtration rate (GFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. In the urine, parameters of oxidative stress were spectrofotometrically determined: levels of superoxide anion radical (O2 ??), hydrogen peroxide (H2O2), nitrites (NO2-) and concentration of thiobarbituric acid reactive substances (TBARS). In hemolysate, the parameters of antioxidant protection: superoxide dismutase (SOD), catalase (CAT) and reduced gluthatione (GSH), were measured. The samples for the analysis were collected three times: before HBOT (initial values), after 10 days of HBOT and 1 month after beginning the treatment in relation to the initial value. Results. We noticed a statistically significant (p &lt; 0.05) decrease in a level of O2 ??, both after 10 days and after 1 month of HBOT (8.26 ? 13.62; 8.39 ? 4.94; 11.92 ? 6.86 nmol/mL, respectively). Values of other parameters of oxidative stress such as NO2-, TBARS and H2O2- showed no significant difference during the monitored period. Regarding the parameters of antioxidant the protection, we revealed slightly higher value of GSH after treatment (initial value: 66.34 ? 16.31; after 10 days of HBOT 79.43 ? 36.77; after 1 month of HBOT69.72 ? 22.32 ?mol/mL red blood cells) which was held after a month, but it was not statistically significant. Activity of SOD and CAT, before and after HBOT, did not change significantly. Conclusion. Our results suggested the potential beneficial effects of HBOT on redox status in the patients with SLE by decreasing the levels of O2??.

The Effect of Hyperbaric Oxygen Therapy on Erectile Functions: A Prospective Clinical Study

Introduction: We aimed to evaluate the effects of hyperbaric oxygen therapy (HBOT) on erectile function in patients who had no cavernosal or urethral injury by using International Index of Erectile Function (IIEF) questionnaire. Materials and Methods: The male patients who were treated by HBOT for several diseases between July 2017 and September 2017 were examined. All patients filled the IIEF questionnaire form before the first day and after the last day of HBOT and a questionnaire including demographic characteristics and medical history. The effects of demographic characteristics and risk factors on erectile function were evaluated, and the IIEF domain scores of patients in first day and last day of HBOT were compared. Results: Totally, 50 patients were included in the study between July 2017 and September 2017 and the mean age was 59.38 ± 13.77. The mean post-HBOT IIEF-EF score of patients was significantly higher than the mean pre-HBOT IIEF-EF score of patients (15.74 ± 10.52 vs. 19.50 ± 10.91; p < 0.001). The mean post-HBOT IIEF scores of other domains including intercourse satisfaction, orgasmic function, sexual desire, and overall satisfaction were also significantly higher than pre-HBOT scores. Conclusions: HBOT may be a good alternative treatment or adjunctive treatment for erectile dysfunction.

25 - The effect of hyperbaric oxygen therapy on erectile functions: A prospective clinical study

INTRODUCTION We aimed to evaluate the effects of hyperbaric oxygen therapy (HBOT) on erectile function in patients who had no cavernosal or urethral injury by using International Index of Erectile Function (IIEF) questionnaire. MATERIALS AND METHODS The male patients who were treated by HBOT for several diseases between July 2017 and September 2017 were examined. All patients filled the IIEF questionnaire form before the first day and after the last day of HBOT and a questionnaire including demographic characteristics and medical history. The effects of demographic characteristics and risk factors on erectile function were evaluated, and the IIEF domain scores of patients in first day and last day of HBOT were compared. RESULTS Totally, 50 patients were included in the study between July 2017 and September 2017 and the mean age was 59.38 ± 13.77. The mean post-HBOT IIEF-EF score of patients was significantly higher than the mean pre-HBOT IIEF-EF score of patients (15.74 ± 10.52 vs. 19.50 ± 10.91; p < 0.001). The mean post-HBOT IIEF scores of other domains including intercourse satisfaction, orgasmic function, sexual desire, and overall satisfaction were also significantly higher than pre-HBOT scores. CONCLUSIONS HBOT may be a good alternative treatment or adjunctive treatment for erectile dysfunction.

Effect of hyperbaric oxygen on BDNF-release and neuroprotection: Investigations with human mesenchymal stem cells and genetically modified NIH3T3 fibroblasts as putative cell therapeutics.

Hyperbaric oxygen therapy (HBOT) is a noninvasive widely applied treatment that increases the oxygen pressure in tissues. In cochlear implant (CI) research, intracochlear application of neurotrophic factors (NTFs) is able to improve survival of spiral ganglion neurons (SGN) after deafness. Cell-based delivery of NTFs such as brain-derived neurotrophic factor (BDNF) may be realized by cell-coating of the surface of the CI electrode. Human mesenchymal stem cells (MSC) secrete a variety of different neurotrophic factors and may be used for the development of a biohybrid electrode in order to release endogenously-derived neuroprotective factors for the protection of residual SGN and for a guided outgrowth of dendrites in the direction of the CI electrode. HBOT could be used to influence cell behaviour after transplantation to the inner ear. The aim of this study was to investigate the effect of HBOT on the proliferation, BDNF-release and secretion of neuroprotective factors. Thus, model cells (an immortalized fibroblast cell line (NIH3T3)–native and genetically modified) and MSCs were repeatedly (3 x – 10 x) exposed to 100% oxygen at different pressures. The effects of HBO on cell proliferation were investigated in relation to normoxic and normobaric conditions (NOR). Moreover, the neuroprotective and neuroregenerative effects of HBO-treated cells were analysed by cultivation of SGN in conditioned medium. Both, the genetically modified NIH3T3/BDNF and native NIH3T3 fibroblasts, showed a highly significant increased proliferation after five days of HBOT in comparison to normoxic controls. By contrast, the number of MSCs was decreased in MSCs treated with 2.0 bar of HBO. Treating SGN cultures with supernatants of fibroblasts and MSCs significantly increased the survival rate of SGN. HBO treatment did not influence (increase / reduce) this effect. Secretome analysis showed that HBO treatment altered the protein expression pattern in MSCs.

Myopic Shift during Hyperbaric Oxygenation Attributed to Lens Index Changes.

To examine ocular lens parameters and structural changes to elucidate mechanisms underlying the myopic shift and cataract-related changes that occur in some patients during hyperbaric oxygen (HBO) therapy. Scheimpflug images (Nidek EAS-1000) of the crystalline lens, measurements of scattered light, objective refraction, keratometry, tonometry, and axial length of the eye were obtained after the first day of HBO therapy and repeated when patients had completed 19 days of the treatment. Significant reduction in mean (± SD) optical density was found in the lens nucleus, -2.8 (± 4.3) units (p = 0.009) and -2.2 (± 4.1) units (p = 0.027) within circular and oval areas, respectively. Significant decrease in mean (± SD) backward scattered light was measured, -0.4 (± 0.8) units (p = 0.022). Mean (± SD) myopic shift was -0.58 (± 0.39) diopters (p < 0.001), whereas cortical optical density, forward scattered light, lenticular parameters, keratometry, tonometry, anterior chamber depth, and axial length of the eye appeared unchanged. Transient myopic shift reported in patients during HBO therapy is attributed to changes in the refractive index of the lens. No changes in lens curvatures or thickness were found after treatment.